CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semprus BioSciences, Corp., a biomedical company developing a proprietary vascular access product platform, today announced the company has received a $500,000 Phase II-B Grant from the National Science Foundation (NSF). This funding will support Semprus BioSciences’ product line featuring its long acting Semprus Sustain™ Performance. This unique technology is the first non-leaching single surface modification that simultaneously reduces bacterial growth and thrombus formation (blood clots) on medical devices with multi-month efficacy, according to the company.
